

a boy, James Phipps, involved the removal of fluid from a cowpox lesion on the hand of Sarah Nelmes. The fluid was inserted into two incisions in the skin of Phipps' arm. After 7 days the boy became slightly unwell, but soon recovered (88). Vaccination had a basis in the earlier practice of variolation, which had been practiced in China as early as the Sung Dynasty (AD 960–1280) (89).

c. Cytokines

The cytokines encompass three categories of molecules, namely, cytokines, chemokines, and certain growth factors (90). Interferon was the first cytokine to be described, as documented in a paper from 1957 (91). Cytokines function

as autocrine signals (secretion and stimulation of the same cell), paracrine and juxtacrine signals (stimulation of nearby cells), or endocrine signals (circulating in the peripheral blood to act on cells remote to the source of production). A small proportion of cytokines have been used as drugs. For example, IL-12 (92), IFN-gamma (93), and IFN-alpha (94), have been tested, or are in actual use, for treating various cancers and immune disorders. The cytokine, granulocyte-macrophage colony-stimulating factor, has shown promising results for treating melanoma (95), lymphoma (96), and breast cancer (97). Interferon, in combination with a small molecule (ribavirin), was formerly the gold standard for treating HCV infections (98).

⁸⁸Morgan AJ, Parker S. Translational mini-review series on vaccines: the Edward Jenner Museum and the history of vaccination. *Clin. Exp. Immunol.* 2007;147:389–94.

⁸⁹Oldstone MBA. *Viruses, plagues, and history: past, present and future.* New York: Oxford University Press; 2009. p. 74.

⁹⁰Tarrant JM. Blood cytokines as biomarkers of in vivo toxicity in preclinical safety assessment: considerations for their use. *Toxicol. Sci.* 2010;117:4–16.

⁹¹Isaacs A, Lindenmann J. Virus interference. I. The interferon. *Proc. R. Soc. Lond. B Biol. Sci.* 1957;147:258–67.

⁹²Alatrash G, Hutson TE, Molto L, et al. Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma. *J. Clin. Oncol.* 2004;22:2891–900.

⁹³Miller CH, Maher SG, Young HA. Clinical use of interferon-gamma. *Ann. N. Y. Acad. Sci.* 2009;1182:69–79.

⁹⁴Bottomley A, Coens C, Suci S, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group. *J. Clin. Oncol.* 2009;27:2916–23.

⁹⁵Sato T, Eschelmann DJ, Gonsalves CF, et al. Immunoembolization of malignant liver tumors, including uveal melanoma, using granulocyte-macrophage colony-stimulating factor. *J. Clin. Oncol.* 2008;26:5436–42.

⁹⁶Cartron G, Zhao-Yang L, Baudard M, et al. Granulocyte-macrophage colony-stimulating factor potentiates rituximab in patients with relapsed follicular lymphoma: results of a phase II study. *J. Clin. Oncol.* 2008;26:2725–31.

⁹⁷Emens LA, Asquith JM, Leatherman JM, et al. Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation. *J. Clin. Oncol.* 2009;27:5911–8.

⁹⁸Lee S, Kim IH, Kim SH, et al. Efficacy and tolerability of pegylated interferon-alpha2a plus ribavirin versus pegylated interferon-alpha2b plus ribavirin in treatment-naive chronic hepatitis C patients. *Intervirology* 2010;53:146–53.